Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Placebo-Controlled, Randomized, Phase Ib Clinical Study of ApTOLL for the Treatment of COVID-19

Next Previous
Trial Profile

A Double Blind, Placebo-Controlled, Randomized, Phase Ib Clinical Study of ApTOLL for the Treatment of COVID-19

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ApTOLL (Primary)
  • Indications COVID 2019 infections; Cytokine release syndrome
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 04 Aug 2023 Status changed from recruiting to discontinued due to lack of patients due to reduced incidence in the COVID-19 infected population in Spain.
  • 28 Sep 2022 Planned End Date changed from 1 Jul 2022 to 1 Jan 2023.
  • 28 Sep 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jan 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top